[8-K] Leap Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Leap Therapeutics, Inc. (LPTX) filed a Form 8-K reporting an item related to Results of Operations and Financial Condition and furnished a press release as an exhibit. The filing identifies Item 9.01 (Financial Statements and Exhibits) and lists Exhibit 99.1 as a press release dated August 14, 2025. The disclosure is signed by Douglas E. Onsi, Chief Executive Officer and President. The document does not include financial statements, earnings figures, transaction details, or other substantive operational data within the provided text.

Insights

Securities Analyst

TL;DR: Routine Form 8-K furnishing a press release; filing itself contains no financial details to assess impact.

The company furnished a press release as Exhibit 99.1 under Item 9.01, indicating an update on results of operations and financial condition was communicated externally. The 8-K text provided here contains no financial metrics, earnings, or material transaction details, so there is nothing in the filing to quantify impact on valuation or near-term guidance. For material assessment, the attached press release (Exhibit 99.1) would need to be reviewed.

Corporate Governance Expert

TL;DR: Properly executed disclosure with CEO signature; content provided is procedural and non-material until exhibit content is reviewed.

The filing follows required disclosure formality by identifying the applicable rules and listing the furnished exhibit. Signature by the CEO is included, confirming authorized filing. Because the body of the 8-K here contains only exhibit references and no substantive operational or financial data, it should be classified as procedural disclosure pending review of Exhibit 99.1 for material content.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/14/2025 - 07:11 AM Learn about SEC filing dates

false 0001509745 0001509745 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2025

Leap Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37990		27-4412575
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47 Thorndike Street, Suite B1-1 Cambridge, MA	02141
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 714-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	LPTX	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition

On August 14, 2025, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025.  The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits.

Exhibit Number		Description
99.1		Press Release of Leap Therapeutics, Inc. dated August 14, 2025.
104		Cover Page Interactive Data File. (Embedded within the Inline XBRL document.)

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LEAP THERAPEUTICS, INC.
Dated: August 14, 2025	By:	/s/ Douglas E. Onsi
	Name:	Douglas E. Onsi
	Title:	Chief Executive Officer and President